

02 Apr 2013	
Close (NTD)	43.5
3M target price (NTD)	45.4
12M target price (NTD)	45.4

Last report date, rating,									
previous close									
3/25/2013	BUY	42.1							
1/22/2013	BUY	39.45							
11/16/2012	NEUTRAL	38.3							
Com	pany informa	tion							
Paid-in capital (NTD mn) 2									
Market cap (10.1								
BVPS (NTD)	34.75								
FINI holding	FINI holding (%)								
Local fund h	0.06								
Major sharel	15.82								
Margin buyir	2,757								

Product mix



Share performance relative to TAIEX



Wah Lee (3010 TT)

BUY

Penetration into biotech/medical business; core business to grow coupled with rising contribution from non-operating business

- Key takeaways:
- (1) 1Q13 revenue to beat expectation on booming shipment of FPD product and steady demand for solar product: 1Q is typically the low season. However, JAN13 revenue recovered to NTD2.82bn on account of booming shipment of LCD timing control IC. Growth momentum of tablet and smartphone shipment resumed starting in MAR13. Therefore, the company's shipments of FPD (LCD timing control IC), engineering plastic, and PCB equipment are expected to rise in 1Q13. Topped with steady demand for solar product, 1Q13 revenue is estimated at NTD7.607bn (-2.76% QoQ and -1.65% YoY), exceeding our expectation. 1Q13 EPS is forecasted at NTD1.04.
- (2) Growth momentum to resume for all product lines in FY13:
- Major growth drivers in FY13 is as follows: a) sustainable shipment of high-end plastic material applied in IT engineering; b) timing controller IC and driver IC shipments to 8.5G fabs in China after Wah Lee becomes a supplier of two major panel makers in Taiwan; c) FY13 revenue derived from touch panel controller IC is estimated to grow by >50% YoY.
- Semiconductor segment: Wah Lee is an agent of JSR Corp's CMP slurry product. Having gained certification approval from TSMC (2330TT), CMP slurry shipment commenced in small volume at present. Revenue contribution of CMP slurry is estimated to grow notably (to exceed NTD10mn per month) in FY14. The CMP slurry business is expected to become a key growth driver in FY13.
- Green-energy segment: Shipment of optical-electronics and green energy related products is expected to improve in FY13. Furthermore, FY13 shipment of LiFePO4 (Lithium iron phosphate) material is expected to increase in FY13. Wah Lee is the authorized distributor for Tatung Fine Chemical's (4738 TT) LiFePO4 product.
- (3) Wah Lee's non-operating income to grow in FY13: Three subsidiaries of the Wah Lee Group are expected to go through IPO in FY13. Therefore, the company's earnings from non-operating investments are forecasted to exceed NTD500mn in FY13 from NTD420mn in FY12.
- (4) Operation to bottom out; recommend BUY: Wah Lee strives to penetrate into the biotech/medical market. In the short term, the company becomes the authorized distributor of pharmaceutical and chemical materials from Japan. In the mid/long term, the company is expected to penetrate into the markets of dietary supplement and medical equipment. FY12 unaudited net profit arrived at NTD981mn with EPS of NTD4.24 based on paid-in capital of NTD2.314bn. The company is estimated to distribute cash dividend of NTD2.5. FY13 EPS is forecasted at NTD5.04 given growth across all products line and rising contribution from non-operating business. Reiterate BUY with TP of NTD45.4.



(Unit: NTD mn)	2011	2012	2013F	4Q11	1Q12	2Q12	3Q12	4012	1013E	2013F	3Q13F	4Q13F
()												
Sales	31,225	31,545	33,443	7,011	7,734	8,279	7,709	7,822	7,607	8,215	9,037	8,585
Gross profit	2,822	2,858	3,049	424	684	755	780	639	685	752	831	781
Operating profit	940	834	992	36	233	228	241	133	193	236	293	270
Net profit	952	981	1,167	25	241	221	295	224	240	277	338	311
EPS (NTD)	4.12	4.24	5.04	0.11	1.04	0.95	1.27	0.97	1.04	1.20	1.46	1.35
Gross margin (%)	9.04%	9.06%	9.12%	6.05%	8.85%	9.12%	10.11%	8.17%	9.00%	9.15%	9.20%	9.10%
Operating margin (%)	3.01%	2.65%	2.97%	0.51%	3.01%	2.75%	3.12%	1.70%	2.53%	2.88%	3.24%	3.14%
Net margin (%)	3.05%	3.11%	3.49%	0.36%	3.12%	2.67%	3.82%	2.87%	3.16%	3.37%	3.74%	3.63%
Sales YoY/QoQ (%)	15.55%	1.03%	6.02%	-5.45%	10.31%	7.05%	-6.88%	1.47%	-2.76%	8.00%	10.00%	-5.00%
Net profit YoY/QoQ (%)	-32.45%	3.03%	18.93%	-88.87%	849.40%	-8.51%	33.61%	-23.88%	6.95%	15.45%	22.08%	-7.98%

Source: TEJ; Capital Securities estimates

Note: EPS estimate is based on paid-in capital of NTD2.314bn

■ Contribution from non-operating businesses to rise in FY13

- (1) Three subsidiaries of the Wah Lee Group are expected to go through IPO in FY13. In particular, Wah Lee holds a stake in Onano Industrial (6405 TT), a manufacturer of glass substrate thinning. Chang Wah Electromaterials (8070 TT) holds a stake in How Wei, a maker of electronic and communication components. Wah Hong Industrial (8240 TT) holds a stake in Jun Hong Optronics, a supplier of touch ITO film.
- (2) Onano Industrial was listed at Gre-Tai Securities Market in DEC12. Wah Lee currently has a 6% stake in Onano Industrial. Onano's FY12 EPS is estimated to exceed NTD10.0 on the back of strong demand for glass substrate thinning from optoelectronics product. Wah Lee's gain on disposal of Onano's stake is estimated at >NTD200mn.
- (3) How Wei is a supplier of power plug/socket. Revenue generated by handset and tablet related products accounts for >70% of its overall revenue while revenue derived from automobile components accounts for 30% of its overall revenue. How Wei has penetrated into Apple's supply chain. How Wei is expected to have its IPO listing in Taiwan in FY14.
- (4) Jun Hong Optronics is a supplier of touch ITO film. Jun Hong has two production lines of ITO film at the stage. Demand for high-end touch ITO film far exceeds supply of high-end ITO film. Jun Hong breaks even at present thanks to improved yield rate on collaboration with Japanese vendors.




Exhibit 1: Quarterly profit in FY11 and FY12 (Unit: NTD mn; %)



Source: Company; Capital Securities

Exhibit 2: Annual revenue during FY08-12



Source: Company; Capital Securities




Exhibit 3: Wah Lee's penetration into the biotech business

Category	Short term (within 1 year)	Mid term (within 2 years)	Long term (>2 years)
Pharmaceutical business	Excipients (Japan) Additive (Taiwan)		
Biotech	Biochemical material (distributorship in discussion with Japanese suppliers)		
Medical consumables	Plastic material (Taiwan, in evaluation Class 1 and Class 2 medical corrections of Consumables for aesthetic medical distributorship)		
Medical consumables	Medical equipment (Japan, in evaluation for distributorship)	apan)	
Dietary supplement	Dietary supplement (Taiwan) Material and dietary supplement distributorship)		

Source: Company; Capital Securities

Exhibit 4: Dividends during FY07-12



Source: TEJ; Capital Securities



Balance sheet

(NTD mn)	2009	2010	2011	2012E	2013F
<u>Assets</u>	15,026	17,491	18,890	19,828	22,547
Current assets	10,958	13,266	14,088	14,787	16,814
Cash & cash equivalents	2,087	1,552	2,112	2,217	2,521
Accounts receivable	5,602	7,303	7,793	7,873	8,346
Inventories	2,456	3,425	3,229	3,261	3,455
L/T investments	2,739	2,957	3,486	3,486	3,486
Fixed assets	916	903	898	1,433	1,933
<u>Liabilities</u>	7,784	9,676	10,781	11,317	12,868
Current liabilities	6,376	8,106	8,568	8,994	10,227
Accounts payable	3,511	4,513	4,334	4,377	4,638
Long-term liabilities	1,049	1,041	1,569	1,647	1,873
Other liabilities	359	529	644	676	768
Shareholders' equity	7,242	7,814	8,109	8,512	9,678
Share capital	2,344	2,314	2,314	2,314	2,314
Retained earnings	2,126	2,766	2,767	3,170	4,336
<u>Liabilities &</u> <u>shareholders' equity</u>	15,026	17,491	18,890	19,828	22,547

Source: TEJ; Capital Securities

Cash flow statement

Odsh now statement											
(NTD mn)	2009	2010	2011	2012E	2013F						
Operating cash flows	2,540	-390	604	952	718						
Net income	810	1,410	952	981	1,167						
Depreciation & amortization	107	106	103	103	164						
Increase in working capital	1,105	578	359	794	794						
Other operating cash flows	517	-2,484	-811	-926	-1,407						
Investing cash flows	-483	-43	-607	-607	-607						
Capital expenditures	-6	36	-593	-593	-593						
Free cash flow	2,534	-354	11	359	125						
Other investing cash flows	-477	-79	-14	-14	-14						
Financing cash flows	-1,478	28	422	-241	193						
Dividends paid	-352	-532	-810	-578	0						
Other financing cash flows	-1,126	560	1,232	338	193						
Increase in cash & cash equivalents	543	-535	560	105	304						
Cash & cash equivalents - year begin	1,544	2,087	1,552	2,112	2,217						
Cash & cash equivalents - year end	2,087	1,552	2,112	2,217	2,521						

Source: TEJ; Capital Securities

Income statement

(NTD mn)	2009	2010	2011	2012E	2013F	
Revenue	19,226	27,023	31,225	31,545	33,443	
Cost of sales	16,910	23,823	28,403	28,687	30,394	
Gross profit	2,316	3,200	2,822	2,858	3,049	
Operating expenses	1,639	2,028	1,882	2,023	2,057	
Operating profit	677	1,172	940	834	992	
EBITDA	1,228	1,967	1,524	1,432	1,629	
Non-operating items	370	640	410	481	450	
Pre-tax profit	1,047	1,812	1,350	1,315	1,442	
Income taxes	237	402	398	334	275	
Net income	810	1,410	952	981	1,167	
Basic EPS (NTD)	3.50	6.09	4.12	4.24	5.04	
Diluted EPS (NTD)	3.50	6.09	4.12	4.24	5.04	

Source: TEJ; Capital Securities

Ratio analysis

(NTD mn)	2009	2010	2011	2012F	2013F
Growth analysis (%)					
Revenue	-20.8%	40.6%	15.5%	1.0%	6.0%
Gross profit	-22.6%	38.2%	-11.8%	1.3%	6.7%
Operating profit	-35.9%	73.1%	-19.8%	-11.2%	18.9%
Net income	9.3%	74.0%	-32.4%	3.0%	18.9%
Profitability analysis (%)					
Gross margin	12.1%	11.8%	9.0%	9.1%	9.1%
EBITDA margin	6.4%	7.3%	4.9%	4.5%	4.9%
Operating margin	3.5%	4.3%	3.0%	2.6%	3.0%
Net margin	4.2%	5.2%	3.0%	3.1%	3.5%
Return on asset	6.2%	9.3%	5.9%	5.1%	5.5%
Return on equity	12.2%	19.5%	12.7%	11.8%	12.8%
Debt & liquidity analysis					
Debt ratio	51.8%	55.3%	57.1%	57.1%	57.1%
Debt-to-equity ratio	107.5%	123.8%	133.0%	133.0%	133.0%
Current ratio	171.9%	163.7%	164.4%	164.4%	164.4%
Activity analysis					
Inventory days	64.8	45.1	42.8	41.3	40.3
Accounts receivable days	99.4	87.2	88.2	90.6	88.5

Source: TEJ; Capital Securities



Quarterly inc	ome statemer	١t
---------------	--------------	----

Quarterly income statement	1011	2011	2011	4011	1012	2012	2012	4012	1012E	1012F	2012E	4012E
(NTD mn)	1Q11	2Q11	3Q11	4Q11	1Q12	2Q12	3Q12	4Q12	1Q13E	2Q13F	3Q13F	4Q13F
Sales	8,588	8,210	7,415	7,011	7,734	8,279	7,709	7,822	7,607	8,215	9,037	8,585
Gross profit	918	833	647	424	684	755	780	639	685	752	831	781
Operating expenses	517	487	490	388	452	527	539	506	492	515	538	512
Operating profit	401	346	156	36	233	228	241	133	193	236	293	270
Non-operating income	140	162	170	40	112	121	186	184	120	120	140	130
Non-operating expenses	19	21	34	27	37	28	40	17	20	10	10	20
Pre-tax profit	522	487	293	48	307	321	387	300	293	346	423	380
Net profit	364	334	228	25	241	221	295	224	240	277	338	311
Paid-in capital	231	231	231	231	231	231	231	231	231	231	231	231
EPS (NTD)	1.57	1.44	0.99	0.11	1.04	0.95	1.27	0.97	1.04	1.20	1.46	1.35
Operating efficiency												
Gross margin (%)	10.69%	10.15%	8.72%	6.05%	8.85%	9.12%	10.11%	8.17%	9.00%	9.15%	9.20%	9.10%
Operating margin (%)	4.67%	4.22%	2.11%	0.51%	3.01%	2.75%	3.12%	1.70%	2.53%	2.88%	3.24%	3.14%
Net margin (%)	4.24%	4.07%	3.08%	0.36%	3.12%	2.67%	3.82%	2.87%	3.16%	3.37%	3.74%	3.63%
QoQ (%)												
Sales	20.67%	-4.41%	-9.68%	-5.45%	10.31%	7.05%	-6.88%	1.47%	-2.76%	8.00%	10.00%	-5.00%
Operating profit	94.91%	-13.76%	-54.78%	-76.96%	545.10%	-2.03%	5.58%	-44.57%	44.52%	22.66%	23.90%	-7.93%
Pre-tax profit	90.32%	-6.73%	-39.81%	-83.47%	534.85%	4.41%	20.44%	-22.35%	-2.50%	18.34%	22.08%	-10.22%
Net profit	73.76%	-8.25%	-31.70%	-88.87%	849.40%	-8.51%	33.61%	-23.88%	6.95%	15.45%	22.08%	-7.98%
YoY (%)												
Sales	43.50%	17.69%	6.76%	-1.49%	-9.95%	0.85%	3.97%	11.57%	-1.65%	-0.77%	17.22%	9.75%
Operating profit	48.53%	-5.18%	-52.78%	-82.49%	-42.04%	-34.15%	53.74%	269.87%	-17.14%	3.75%	21.75%	102.22%
Pre-tax profit	12.99%	-2.47%	-49.17%	-82.34%	-41.09%	-34.06%	31.95%	519.90%	-4.80%	7.90%	9.37%	26.46%
Net profit	-0.34%	-11.11%	-50.20%	-87.88%	-33.79%	-33.98%	29.16%	783.41%	-0.48%	25.59%	14.75%	38.72%

Source: TEJ; Capital Securities



STOCK RATING

STRONG BUY

Based on the last closing price prior to our initial STRONG BUY recommendation, our 3-month target price implies upside exceeding or equal to 35%

BUY

Based on the last closing price prior to our initial BUY recommendation, our 3-month target price implies upside between 15% and 35%.

NEUTRAL

We are unable to issue investment recommendation based on the company's current fundamentals. We expect the share price to consolidate in the near term and recommend investors to look for a better entry point.

Disclosure

This report is for circulation to Capital Securities Corp. clients only. This report or any portion hereof may not be reprinted, sold, or redistributed without the written consent of Capital Securities Corp. Readers of this report must understand and accept that their actions at the time that they access this report fall under the jurisdiction of the ROC law, even if viewed from outside of Taiwan, Republic of China.

This report is written for information purposes only. Capital Securities Corp. makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in this report change apart from when we intend to discontinue research coverage of a subject company.

This report does not provide individually tailored investment advice. It has been prepared without regard to the individual financial circumstances and objectives or persons who receive it and is provided with the understanding that Capital Securities Corp. is not acting in fiduciary capacities. The securities discussed in this report may not be suitable for all investors. Capital Securities Corp. recommends that investors independently evaluate particular investment or strategies. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. This report is neither an offer, nor an invitation to buy or sell any security or to participate in any trading strategy.

Compensation of research analysts is determined by equity research department and senior management of Capital Securities Corp. and is not linked to specific transactions or recommendations. The research analysts primarily responsible for the preparation and content of this report certify that all of the views expressed in this report accurately reflect their personal views about those issuers or securities. The research analysts also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Materials presented in this report are based on public information. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, other business units of Capital Securities Corp., including investment banking. We have established information barriers between research and certain business units, including investment banking. Investors should assume that Capital Securities Corp. may seek investment banking or other business opportunities with companies mentioned in this report.

Equity research department of Capital Securities Corp. conducts periodic reviews of research reports to track quality, accuracy and changes in ratings and price targets.

Investors should note that the value of and income from your investment may vary because of changes in interest rate or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors. Additionally, investors in securities such as ADRs, whose values are influenced by the currency of the underlying security, effectively assume currency risk. Estimates of future performance are based on assumptions that may not be realized and should not be relied upon as such.

Additional information on recommended securities is available upon request.